Published Date: 26 Apr 2023
In people with allergic asthma, for instance, a vitamin D3 deficiency can cause severe symptoms. Numerous studies have already demonstrated this. But we're still not sure how exactly this vitamin works.
Read Full NewsSubcutaneous anifrolumab for SLE met its primary BICLA endpoint at 52 weeks and significantly increased DORIS-defined remission and low disease activity.
Stephanie Fradette, PharmD, head of neuromuscular development at Biogen, gave immediate reaction to the EC approval of high-dose nusinersen and its implications for evolving SMA treatment strategies.
A recent phase 2b study reveals mesdopetam's potential in reducing dyskinesia severity in Parkinson disease, despite no significant ON time improvement.
1.
Unraveling the role of exercise in cancer suppression
2.
Medical Journal March 28, 2023
3.
New BCMA-Directed Therapies Show Promise in Multiple Myeloma
4.
FDA Authorizes Three Different Uses for Injectable Antibiotic.
5.
AI is equally capable of reading breast cancer scans as human radiologists.
1.
Targeting BRAF V600E in mCRC: FOLFOX, Cetuximab & Encorafenib Strategies
2.
Symptoms and Causes of Phlegmasia Cerulea Dolens: A Comprehensive Guide
3.
Optimizing Chemotherapy Dosing: From Phase 1 Dose Escalation to Modification
4.
Refining AML Survival: Prognostic Factors, Therapies, and Stem Cell Strategies Reviewed
5.
Feline Anemia: Diagnosis and Treatment with Focus on Rasburicase Complications
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias- The Summary
2.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
3.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation